Veerhealth Care Ltd — Important, 27-06-2026: Company Update

Veerhealth Care's investor presentation highlights key growth drivers. The company achieved USFDA approval in June 2025 for Drug (OTC) products, enabling U.S. exports and a 'Local to Global' expansion. Q4 FY26 revenue from operations impressively reached 16.76 Cr, up from 7.26 Cr in Q3 FY26. Veerhealth also launched VEER PLAST for backward integration in packaging, enhancing efficiency. Its Ayuveer brand expanded market reach by listing on Myntra. The company projects stronger results ahead, supported by facility upgrades and a new partnership with a leading FMCG firm.